Occam Places John McDonald on Board of Geron

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies, has appointed John F. McDonald to its Board.

John currently serves as Corporate Vice President, Global R&D Business Development, for Novo Nordisk A/S, where he leads R&D business development activities and investment strategies. From 2011 to 2018, John was Vice President, Business Development, at Biogen Inc. and prior to that role, served as Managing Director at MPM Capital LP.  His earlier career includes roles across business development, corporate strategy, and legal at various biopharmaceutical companies.

John holds a J.D. from University of California Hastings College of the Law and an M.B.A. and B.S. from the Haas School of Business, University of California, Berkeley.

Geron is a longstanding client for whom Occam had previously placed two independent Board members, Dawn Bir and Liz O’Farrell, and more recently, Chief Business Officer Edward Koval and VP Investor Relations & Corporate Communications Aron Feingold.

Occam Places Bimal Shah as CFO of Corium

Bimal Shah joins Corium, a commercial-stage CNS biopharma and Gurnet Point Capital investment, as Chief Financial Officer, bringing with him substantial experience in healthcare private equity investments, M&A, and other strategic transactions.  He also has industry experience in corporate strategy and commercial assessments with expertise in specialty pharmaceuticals, biotech, medical devices, contract research and manufacturing services, clinical and lab services, and distribution.

Prior to joining Corium, Bimal served as Senior Vice President, Corporate Finance and Strategy, for Sumitovant Biopharma, a wholly-owned subsidiary of Sumitovant Dainippon Biopharma, one of Japan’s largest pharmaceutical companies. While at Sumitovant, he had oversight for financial planning and analysis, corporate finance and strategy, among other responsibilities.

Bimal previously held roles in the business development, finance and strategic functions at various biotech companies, including Genentech. His earlier career occurred on Wall Street with Goldman Sachs and Warburg Pincus, where he focused on the life sciences and healthcare verticals and was responsible for a wide range of creative transactions, including financings, investments, acquisitions and alliances.

Bimal received his Master’s in Business Administration, Master of Arts in International Policy Studies and bachelor’s degrees from Stanford University.

Occam Places Bell Zhong as CFO at Neomorph

Neomorph, an induced proximity platform company which raised a $109 Million A round led by Deerfield, has added Bell Zhong as Chief Financial Officer. 

Neomorph is focused on solving critical problems in human health through the discovery and development of innovative new medicines against “undruggable targets.”

Zhong brings nearly two decades of investment banking and corporate finance leadership experience in the healthcare and life sciences sector. Bell joins Neomorph from Raymond James where he was Managing Director covering the biotechnology sector, responsible for advising companies of all stages of development on a wide array of financing and strategic transactions. Previously, Bell spent over 13 years at J.P. Morgan, where most recently he served as Executive Director in the firm’s leading Healthcare Investment Banking practice.

Occam Places Padma Sundar as CBO at ChromaCode

ChromaCode, a private molecular diagnostics company with a bioinformatics focus, has added Padma Sundar as Chief Business Officer to lead commercialization. The company was founded by Illumina veteran Alex Dickinson and has NEA and Northpond as lead investors.

Padma brings deep knowledge of the cancer space and nearly two decadesdiagnostic  She most recently served as Chief Commercial Officer of Oncocyte, a precision diagnostics company.

Her career began in the healthcare practice of McKinsey &Co.

Padma earned both an MBA and an MPH from the University of California-Berkeley after completing her undergraduate degree in Chemistry at Delhi University.

Occam Places Jorge Bartolome as CEO at Areteia Therapeutics

Areteia Therapeutics, a private clinical stage biotech that just raised $350M in a Series A led by Bain Capital, is the product of a collaboration between Clive Meanwell’s Population Health Partners and Knopp Biosciences. The recent robust financing round will be used to advance its lead candidate, dexpramipexole, a small molecule in phase 3 development, one holding out great promise as the first oral therapy for asthma. If successful, this compound represents a potential game changing treatment for an ubiquitous and difficult to treat chronic condition.

Jorge enters the fray at a critical point in the company’s evolution. He  brings powerful domain expertise and decades of commercial leadership to the party. Previously, Bartolome served as President of Canada for Janssen and, prior to that, as SVP of the US Respiratory Business Unit of GSK.

See Full Press Release HERE

Chris Gibson

CEO | Recursion Pharmaceuticals

"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."
Find out more Read the Case Study

Julie Sunderland

Managing Director | Biomatics Capital

"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."
Find out more

Josh Wolfe

Co-Founder & Managing Partner | Lux Capital

"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."
Find out more

Bob More

Managing Director | Alta Partners

"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."
Find out more

Frederic Kerrest

Executive Vice Chairperson, COO & Co-Founder | Okta

“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”
Find out more

Recent Placements

Occam Places John McDonald on Board of Geron

Find out more

Occam Places Bimal Shah as CFO of Corium

Find out more

Occam Places Bell Zhong as CFO at Neomorph

Find out more

Occam Places Padma Sundar as CBO at ChromaCode

Find out more

Occam Places Jorge Bartolome as CEO at Areteia Therapeutics

Find out more

Why Occam?

Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.

Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.

The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.

  • Rich expertise and global contacts in technology, healthcare, financial services, and entrepreneurial organizations
  • Objective yet unconventional approach to problem solving
  • Virtually no off-limits constraints
  • Milestone-driven fee structure
Meet our executive headhunters

Services

Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.

Executive Search

Find out more
+
Executive
Placements
+
Board
Placements

Board of Directors Search

Find out more

Human Venture Capital

Find out more

Industries

Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.

  • Biotechnology
  • Pharmaceuticals
  • Life Sciences
  • Medical Devices
  • Healthcare
  • Technology
  • FinTech
  • Sustainable Energy
  • Venture Capital
  • Private Equity

Select Clients

  • Recursion Pharamceuticals
  • Elicio Therapeutics
  • PACT Pharma
  • Pacira Biosciences Inc.
  • Tmunity
  • CytomX Therapeutics
  • Generation Bio
  • Beam Therapeutics
  • Variant Bio
  • Semma Therapeutics
  • eGenesis Engineering
  • Oncorus
Previous Slide Next Slide

News & Views

Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.

View all news

Occam Places John McDonald on Board of Geron

Read Story

Occam Places Bimal Shah as CFO of Corium

Read Story

Occam Places Bell Zhong as CFO at Neomorph

Read Story

Occam Places Padma Sundar as CBO at ChromaCode

Read Story

Occam Places Jorge Bartolome as CEO at Areteia Therapeutics

Read Story

Occam Recruits Michael Miller to the Board of BioXcel

Read Story

Contact

145 Hudson Street, Suite 5B
New York, NY, 10004
United States

    I am interested in*